Patrick Eulitt, MD
Medical Oncology · Lone Tree, CONPI 1447677489
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $97 of the $143 with a category attached, or 67.7%. 5 manufacturers reported payments, led by Genentech USA, Inc. at 39.2% of the total. That places this record below the midpoint for medical oncology clinicians in CO, where the typical reported total is $1,342.
Across 6 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$56
- Iovance Biotherapeutics, Inc.$41
- Myovant Sciences Inc.$24
- Gilead$12
- Advanced Accelerator Applications$10
Across 36 payments — averaging $28,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$1M
- Pfizer$3K
What the payments were for
- Travel & lodging$107%
- Food & beverage$9768%
- Education$3625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $56 |
| Iovance Biotherapeutics, Inc. | 2 | $41 |
| Myovant Sciences Inc. | 1 | $24 |
| Gilead | 1 | $12 |
| Advanced Accelerator Applications | 1 | $10 |
How this compares
$143 in reported general payments places this provider in the 20th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $283,481 |
| BrukinsaZanubrutinib | 12 | $180,560 |
| EliquisApixaban | 94 | $78,374 |
| XareltoRivaroxaban | 12 | $11,355 |
| Abiraterone Acetate | 28 | $4,349 |
| Fentanyl | 16 | $3,564 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 33 | $803 |
| Prochlorperazine Maleate | 39 | $635 |
| Ondansetron OdtOndansetron | 31 | $534 |
| Prednisone | 58 | $390 |
| Duloxetine Hcl | 24 | $376 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 28 | $371 |
| Pantoprazole Sodium | 12 | $287 |
| Hydroxyurea | 19 | $211 |
| Ondansetron Hcl | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Lone Tree
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Chelsea GawryletzFort Collins$301K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Jose PachecoAurora$50K
- Leonard GlodeAurora$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.